Shopping Cart
- Remove All
- Your shopping cart is currently empty
SPC-180002, a dual SIRT1/3 inhibitor, exhibits IC50 values of 1.13 and 5.41 μM for SIRT1 and SIRT3, respectively. It disrupts redox homeostasis through ROS generation, consequently enhancing p21 protein stability and inducing mitochondrial dysfunction. Furthermore, this compound significantly impedes cell cycle progression and malignancy proliferation, while also activating the Nrf2 signaling pathway [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | SPC-180002, a dual SIRT1/3 inhibitor, exhibits IC50 values of 1.13 and 5.41 μM for SIRT1 and SIRT3, respectively. It disrupts redox homeostasis through ROS generation, consequently enhancing p21 protein stability and inducing mitochondrial dysfunction. Furthermore, this compound significantly impedes cell cycle progression and malignancy proliferation, while also activating the Nrf2 signaling pathway [1]. |
Targets&IC50 | SIRT1:1.13 μM, SIRT3:5.41 μM |
In vitro | SPC-180002 (0-5 µM, 24 hours) inhibits cell cycle progression via accumulation of p21, leading to subsequent cellular senescence [1]. Moreover, SPC-180002 does not induce apoptosis or autophagy [1]. |
In vivo | SPC-180002 (1-5mg/kg, bi-weekly, intraperitoneally) can inhibit the growth of various cancer cells and impede tumor growth in MCF7 xenograft mice [1]. |
Molecular Weight | 317.38 |
Formula | C18H23NO4 |
Cas No. | 2170274-53-8 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.